Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Checked 2026-09-09
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
One cycle
every 6 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Fludarabine | 30 mg/m² per day | IV | D1-3 | days -5 to -3 |
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 500 mg/m² per day | IV | D1-3 | days -5 to -3 |
| product-specific dose, e.g. 2 × 10⁶ CAR-positive cells/kg | IV | D6 | day 0 |
Cycles
single course (days -5 to 0)
6-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Tocilizumab for CRS grade 2 and above; dexamethasone for ICANS. Bridging therapy is often needed during manufacture.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
R-CHOP
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
every 21 days × 6
Pola-R-CHP
Untreated DLBCL, IPI 2-5
every 21 days × 6
R-ICE
Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging
every 14 days × 2-3
Bendamustine + rituximab (BR)
Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable
every 28 days × 6
Blinatumomab
B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)
every 42 days × 2
Inotuzumab ozogamicin
Relapsed or refractory CD22-positive B-ALL
every 21 days
Imatinib
Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST
every 28 days